Bladder cancer therapy without toxicity—A dose‐escalation study of alpha1‐oleate
Open Access
- 22 April 2020
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 147 (9) , 2479-2492
Abstract
Potent chemotherapeutic agents are required to counteract the aggressive behavior of cancer cells and patients often experience severe side effects, due to tissue toxicity. Our study addresses if a better balance between efficacy and toxicity can be attained using the tumoricidal complex alpha1‐oleate, formed by a synthetic, alpha‐helical peptide comprising the N‐terminal 39 amino acids of alpha‐lactalbumin and the fatty acid oleic acid. Bladder cancer was established, by intravesical instillation of MB49 cells on day 0 and the treatment group received five instillations of alpha1‐oleate (1.7‐17 mM) on days 3 to 11. A dose‐dependent reduction in tumor size, bladder size and bladder weight was recorded in the alpha1‐oleate treated group, compared to sham‐treated mice. Tumor markers Ki‐67, Cyclin D1 and VEGF were inhibited in a dose‐dependent manner, as was the expression of cancer‐related genes. Remarkably, toxicity for healthy tissue was not detected in alpha1‐oleate‐treated, tumor‐bearing mice or healthy mice or rabbits, challenged with increasing doses of the active complex. The results define a dose‐dependent therapeutic effect of alpha1‐oleate in a murine bladder cancer model.Keywords
Funding Information
- Gunnar Nilssons Cancerstiftelse
- Lunds Universitet
- Cancerfonden
This publication has 25 references indexed in Scilit:
- A Unifying Mechanism for Cancer Cell Death through Ion Channel Activation by HAMLETPLOS ONE, 2013
- Low Resolution Solution Structure of HAMLET and the Importance of Its Alpha-Domains in Tumoricidal ActivityPLOS ONE, 2012
- Association of Angiogenesis Related Markers With Bladder Cancer Outcomes and Other Molecular MarkersJournal of Urology, 2010
- HAMLET Treatment Delays Bladder Cancer DevelopmentJournal of Urology, 2010
- Emerging targeted therapies for bladder cancer: a disease waiting for a drugCancer and Metastasis Reviews, 2009
- An Individual Patient Data Meta-Analysis of the Long-Term Outcome of Randomised Studies Comparing Intravesical Mitomycin C versus Bacillus Calmette-Guérin for Non–Muscle-Invasive Bladder CancerEuropean Urology, 2009
- Changes in Proteasome Structure and Function Caused by HAMLET in Tumor CellsPLOS ONE, 2009
- Bladder cancers respond to intravesical instillation of (HAMLET human α‐lactalbumin made lethal to tumor cells)International Journal of Cancer, 2007
- HAMLET Interacts with Histones and Chromatin in Tumor Cell NucleiJournal of Biological Chemistry, 2003
- Contemporary Management Of Stage T1 Transitional Cell Carcinoma Of The BladderJournal of Urology, 2002